Lanadelumab's impact on hereditary angioedema control and quality of life across disease activity subgroups: Real-world evidence.

Saved in:
Bibliographic Details
Title: Lanadelumab's impact on hereditary angioedema control and quality of life across disease activity subgroups: Real-world evidence.
Authors: Zanichelli A; Operative Unit of Medicine, Angioedema Center, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Donato, San Donato Milanese, Milan, Italy; Dipartimento di Scienze Biomediche per la Salute, University of Milan, Milan, Italy., Wuillemin WA; Division of Hematology and Hematology Laboratory, Department of Internal Medicine, Luzerner Kantonsspital, Lucerne and University of Berne, Berne, Switzerland., Aygören-Pürsün E; Department for Children and Adolescents, Angioedema Centre, University Hospital Frankfurt, Goethe University, Frankfurt, Germany., Banerji A; Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Busse PJ; Division of Allergy and Clinical Immunology, Icahn School of Medicine at Mount Sinai, New York, New York., Betschel SD; Division of Clinical Immunology and Allergy, University of Toronto, Toronto, Ontario, Canada., Cancian M; Department of Systems Medicine, University Hospital of Padua, Padua, Italy., Gagnon R; Laval University, Centre Hospitalier Universitaire de Québec (CHUL), Québec, Canada., Goodyear MD; Division of Hematology and Hematologic Malignancies, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada., Kinaciyan T; Department of Dermatology, Medical University of Vienna, Vienna, Austria., Kessel A; Division of Allergy and Clinical Immunology, Bnai Zion Medical Centre, Technion Faculty of Medicine, Haifa, Israel., Magerl M; Institute of Allergology, Charité-Universitätsmedizin Berlin (corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin), Berlin, Germany; Immunology and Allergology, Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Immunology and Allergology, Berlin, Germany., Recke A; Department of Dermatology, Allergology and Venereology, University of Lübeck, Lübeck, Germany., Wedner HJ; Division of Allergy and Immunology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri., Estepan DN; Takeda Development Center Americas, Inc, Lexington, Massachusetts. Electronic address: daniel.novaestepan@takeda.com., Watt M; Takeda Development Center Americas, Inc, Lexington, Massachusetts., Andresen I; Takeda Pharmaceuticals International Aktiengesellschaft (AG), Zurich, Switzerland., Juethner S; Takeda Pharmaceuticals USA, Inc., Lexington, Massachusetts., Khutoryansky N; Takeda Development Center Americas, Inc, Lexington, Massachusetts., Martinez-Saguer I; Hämophilie-Zentrum Rhein Main (HZRM), Frankfurt/Main, Germany.
Source: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [Ann Allergy Asthma Immunol] 2025 Nov; Vol. 135 (5), pp. 560-569.e2. Date of Electronic Publication: 2025 Sep 06.
Publication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Observational Study
Journal Info: Publisher: American College of Allergy, Asthma, and Immunology Country of Publication: United States NLM ID: 9503580 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4436 (Electronic) Linking ISSN: 10811206 NLM ISO Abbreviation: Ann Allergy Asthma Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1534-4436
DOI:10.1016/j.anai.2025.07.025